Introduction: Despite evidence of the efficacy of decursinol angelate (DA), a prescription medication derived farom traditional Chinese medicine, in alleviating inflammatory bowel disease (IBD), the precise mechanisms behind its action remain unclear.
Methods: Lipopolysaccharides (LPS) and dextran sodium sulfate (DSS) induction were used as and models of IBD, respectively, to assess the role of DA in alleviating IBD. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the expression levels of pro-inflammatory cytokines in mouse serum, Western blot was performed to detect the expression of TXNIP/NLRP3 pathway tight junction (TJ) proteins in colon tissues and cells, and immunohistochemistry, immunofluorescence and immunohistochemistry, immunofluorescence and qRT-PCR were used to validate the proteins related to this signaling pathway. Molecular docking technique and co-immunoprecipitation (Co-IP) method assay were applied to evaluate the targeting effect of DA on NLRP3 proteins, and MCC950, a specific inhibitor of NLRP3, was used as a positive control for validation.
Results: Our research indicates that DA's distinctive molecular mechanism could entail binding to the NLRP3 protein, thereby suppressing the activation of the NLRP3 pathway and diminishing the assembly and activation of the NLRP3 inflammasome, thus functioning as an anti-inflammatory agent.
Conclusion: DA may play a role in improving BD by inhibiting the activation of the ROS/TXNIP/NLRP3 signaling pathway and the release of inflammatory mediators, and by repairing the intestinal barrier function.
Molecules. 2018 Jul 27;23(8):
[PMID:
30060484]
Curr Protoc Immunol. 2014 Feb 04;104:15.25.1-15.25.14
[PMID:
24510619]
Gut. 2010 Sep;59(9):1192-9
[PMID:
20442201]
Expert Rev Mol Med. 2021 Dec 27;23:e23
[PMID:
34955116]
Int J Biochem Cell Biol. 2017 Mar;84:22-34
[PMID:
28064010]
Carcinogenesis. 2008 Sep;29(9):1799-806
[PMID:
18567620]
Handb Exp Pharmacol. 2017;239:115-146
[PMID:
28233184]
Inflammation. 2020 Feb;43(1):17-23
[PMID:
31646445]
J Ethnopharmacol. 2008 Aug 13;118(3):367-72
[PMID:
18571884]
Front Pharmacol. 2020 Dec 17;11:591393
[PMID:
33390969]
Front Immunol. 2021 Oct 25;12:767456
[PMID:
34759934]
Inflammopharmacology. 2008 Aug;16(4):162-7
[PMID:
18759074]
Methods Mol Biol. 2017;1615:211-219
[PMID:
28667615]
Microb Pathog. 2022 Feb;163:105383
[PMID:
34974120]
Curr Med Chem. 2020;27(13):2059-2076
[PMID:
30182837]
Science. 2018 Nov 23;362(6417):956-960
[PMID:
30467171]
Eur J Pharmacol. 2022 Aug 5;928:175091
[PMID:
35714692]
Antioxid Redox Signal. 2015 May 1;22(13):1111-29
[PMID:
25330206]
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27
[PMID:
26627550]
J Appl Microbiol. 2023 Mar 1;134(3):
[PMID:
36646433]
Biomed Pharmacother. 2018 Aug;104:622-628
[PMID:
29803175]
J Pharm Biomed Anal. 2008 Jan 22;46(2):258-66
[PMID:
17997069]
Intest Res. 2018 Jan;16(1):26-42
[PMID:
29422795]
Sci Total Environ. 2024 Feb 25;913:169730
[PMID:
38160834]
Nat Rev Dis Primers. 2020 Sep 10;6(1):74
[PMID:
32913180]
Curr Top Med Chem. 2018;18(12):1015-1028
[PMID:
30129415]
World J Gastroenterol. 2019 Sep 7;25(33):4796-4804
[PMID:
31543674]
Inflamm Res. 2018 Mar;67(3):209-218
[PMID:
29134229]
